CLAIMS

1. A compound corresponding to formula (I):



(I)

in which:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a) (b) (c)

- L represents a linker $–CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or a (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group and a hydroxyl group;
- R_1 represents:
  - a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group and a trifluoromethyl group,
  - a (C_3-C_6)cycloalkyl group, optionally substituted with a hydroxyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-NH_2$ group, a urea group of formula $–NH-CO-NH-(C_1-C_4)$alkyl, a morpholine group, a group of formula $-SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,

- a hydroxyl group or a (C_1-C_5)alkoxy group,
- a group -COR_3, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group -$CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a group -$NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

- R_2 represents a hydrogen atom when n represents 1 and a methyl group when

n represents 0;

- R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a $(C_1$-$C_3)$alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

2. The compound of formula (I) as claimed in claim 1, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a) (b) (c)

- L represents a linker $–CH_2$-CO- such that the carbonyl function is attached to the substituent R_1, or a $(C_1$-$C_2)$alkyl, said alkyl being optionally substituted with one or more substituents chosen from a $(C_1$-$C_3)$alkyl group and a hydroxyl group;
- R_1 represents:
  - a linear or branched $(C_1$-$C_5)$ alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
  - a $(C_3$-$C_6)$cycloalkyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-NH_2$ group, a urea group of formula –NH-CO-NH-$(C_1$-$C_4)$alkyl, a morpholine group, a group of formula $-SO_2$-$(C_1$-$C_5)$alkyl, a $(C_1$-$C_5)$alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a hydroxyl group or a $(C_1$-$C_5)$alkoxy group,
    - a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
    - a group $-CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
    - a group $-NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
    - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,

- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,

- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,

- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,

- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

3. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

➢ Y represents a bridged morpholine (a)



(a)

in the form of the base or of an addition salt with an acid or with a base.

4. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine (a)



(a)

- L represents a linker $-CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group;
- R_1 represents:
  - a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group, a trifluoromethyl group and a (C_3-C_6)cycloalkyl group,
  - a (C_3-C_6)cycloalkyl group, optionally substituted with a hydroxyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-NH_2$ group, a urea group of formula -NH-CO-NH-(C_1-C_4)alkyl, a morpholinyl group, a group of formula $–SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a hydroxyl group or a (C_1-C_5)alkoxy,
    - a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
    - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
    - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and

an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

5. The compound of formula (I) as claimed in any one of claims 1 to 4, characterized in that:

➢ n represents 0 or 1;

➢ Y represents a bridged morpholine (a)



(a)

➢ L represents a linker $–CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group;

➢ R_1 represents:

- a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- a (C_3-C_6)cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-NH_2$ group, a urea group of formula -NH-CO-NH-(C_1-C_4)alkyl, a morpholinyl group, a group of formula $–SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a hydroxyl group or a (C_1-C_5)alkoxy,
  - a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
  - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
  - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an $-NH_2$ group,
- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents

chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,

- a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,

- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

6. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

➢ n represents 0 or 1;

➢ Y represents a bridged morpholine chosen from (b) and (c)



(b) (c)

➢ L represents a linker –CH_2-CO- such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with a hydroxyl group;

➢ R_1 represents:

- a linear or branched (C_1-C_5)alkyl group, optionally substituted with an aryl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group and a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
  - a group -$CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
  - a group -$NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heteroaryl group comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more (C_1-C_3)alkyl groups, optionally substituted with one or more halogen atoms,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

7. The compound as claimed in any one of claims 1 to 6, characterized in that the linker L represents –CH_2-CO, in the form of the base or of an addition salt with an acid or with a base.

8. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 1, in the form of the base or of an addition salt with an acid or with a base.

9. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 0, in the form of the base or of an addition salt with an acid or with a base.

10. The compound as claimed in any one of claims 1 to 9, characterized in that R_1 represents a heteroaryl group, in the form of the base or of an addition salt with an acid or with a base.

11. The compound as claimed in any one of claims 1 to 9, characterized in that R_1 represents a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group, in the form of the base or of an addition salt with an acid or with a base.

12. The compound as claimed in any one of the preceding claims 1 to 11, characterized in that it is chosen from:

1 (8S)-9-(2-Methyl-2-pyrid-4-ylpropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

2 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

3 (8S)-9-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

4 (8S)-9-[2-(6-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

5 (8S)-9-[2-(6-Methylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

6 (8S)-9-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

7 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

8 1-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(S)-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

9 2-(S)-Methyl-1-[2-(6-methylaminopyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

10 (8S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-

azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

11 (S)-1-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

12 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

13 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

14 (8S)-9-{2-[6-(2-Hydroxyethylamino)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

15 (8S)-9-[2-(5-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

16 2-Methyl-1-[2-(5-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

17 2-Methyl-1-[2-(6-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

18 2-Methyl-1-[2-(2-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

19 (8S)-9-[2-(2-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

20 (8S)-9-[2-(4-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-

4-one

21 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-oxo-2-pyrid-3-yl)ethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

22 (8S)-9-[2-(6-Cyclopropylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

23 1-Ethyl-3-{4-[2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea

24 1-Ethyl-3-{4-[2-((S)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea

25 (8S)-9-[2-(4-Methylthiazol-5-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

26 2-Methyl-1-[2-(4-methylthiazol-5-yl)ethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

27 (8S)-9-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

28 1-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

29 (8S)-9-(3,3-Dimethyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

30 1-(3,3-Dimethyl-2-oxobutyl)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

31 (8S)-9-[2-(6-Amino-5-methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

32 1-[2-(4-Aminophenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

33 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(6-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

34 (8S)-9-(2-{6-[(2-Hydroxyethyl)methylamino]pyrid-3-yl}-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

35 (8S)-9-[2-(6-Ethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

36 (8S)-9-[2-(6-Amino-4,5-dimethylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

37 (S)-9-[2-(4-Difluoromethoxyphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

38 (8S)-9-[2-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

39 (8S)-9-[2-(4-Methyloxazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

40 (S)-9-[2-(3,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

41 (8S)-9-[2-(4-Morpholin-4-ylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

42 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile

43 (8S)-9-[2-(4-Methylthiazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

44 (8S)-9-[2-(5-Chloropyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

45 (8S)-9-[2-(6-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

46 (8S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

47 (8S)-9-(2-Benzo[1,2,3]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

48 (8S)-9-[2-(2,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

49 (8S)-9-(3-Ethyl-3-hydroxypentyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

50 (8S)-9-(3-Hydroxy-3-methylbutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

51 (8S)-9-(1-Methyl-1H-indazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

52 (8S)-9-[2-(2-Cyclopropylmethoxypyrimidin-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

53 (8S)-9-[2-(3,5-Dimethylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

54 (8S)-9-(2-Ethyl-2-hydroxybutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

55 3-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile

56 (8S)-9-(3-Methyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

57 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid ethyl ester

58 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid methyl ester

59 (8S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

60 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(2-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

61 (8S)-9-(2-Benzo[1,2,5]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

62 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

63 (8S)-9-{2-[6-(2-Fluoroethoxy)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

64 (8S)-9-{2-[3-Fluoro-4-(2-fluoroethoxy)phenyl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

65 (8S)-9-[2-(2-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

66 (8S)-9-[2-(3-Methyl-3H-imidazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

67 (8S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

68 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

69 (8S)-9-[2-(2-Methyl-2H-pyrazol-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

70 N,N-Dimethyl-2-(4-{2-[(S)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl]ethyl}phenoxy)acetamide

71 (8S)-9-[(S)-2-(4-Fluoro-2-methoxyphenyl)-2-hydroxyethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

72 (2S)-1-[2-(4-Hydroxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

73 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

74 (2S)-1-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

75 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

76 (S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

77 (S)-2-Methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(3-phenylpropyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

78 (S)-1-{2-[4-(3-Dimethylaminopropoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

79 (2S)-1-((S)-2-Hydroxy-2-phenylethyl)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

80 (8S)-9-((S)-2-Hydroxy-2-phenylethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

81 (8S)-9-[2-(4-Methoxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

82 (8S)-9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxyethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

83 (8S)-9-[2-(4-Hydroxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

84 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(3-phenylpropyl)-8-trifluoromethylmethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

85 (8S)-2-(3-Oxa-8-azabicyclo[3.2.1]oct-8-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

86 (8S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

87 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

88 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

89 (S)-9-[2-(1-Acetylpiperid-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

90 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]piperidine-1-carbaldehyde

91 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carboxylic acid ethyl ester

92 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

93 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(tetrahydropyran-4-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

94 (8S)-9-(1-Acetylpiperid-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

95 4-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carbaldehyde

96 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(3,3,3-trifluoro-2-hydroxy-2-trifluoromethylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

97 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(4,4,4-trifluoro-3-hydroxy-3-trifluoromethylbutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

98 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

99 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

100 (8S)-9-[2-(1-Hydroxycyclopentyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

101 (8S)-9-(1-Hydroxycyclopentylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

102 (8S)-9-(3,3-Dicyclopropyl-3-hydroxypropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

103 (8S)-9-(2,2-Dicyclopropyl-2-hydroxyethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

104 (8S)-9-(1-Hydroxycyclopropylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

105 (8S)-9-[2-(1-Hydroxycyclopropyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

106 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-quinolin-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

107 (8S)-9-[2-(3-Methylisothiazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

108 (8S)-9-[2-(4-Methanesulfonylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

109 (8S)-9-Isoquinolin-5-ylmethyl-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

110 (8S)-9-(2-Morpholin-4-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-

yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

111 (8S)-9-{2-[4-(2-Morpholin-4-ylethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

112 N-Methoxy-N-methyl-2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetamide

113 (8S)-9-(2-Imidazo[1,2-a]pyrid-6-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

114 (8S)-9-[2-(6-Difluoromethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

115 (S)-9-{2-[4-(2-Morpholin-4-yl-2-oxoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

116 (8S)-9-(1-Methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

117 (8S)-9-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

118 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carbaldehyde

119 (8S)-9-[2-(1-Acetylpiperid-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

in the form of the base or of an addition salt with an acid or with a base.

13. A process for preparing a compound of formula (I) as claimed in any one of claims

1 to 12, comprising the reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a bridged morpholine Y, chosen from (a), (b) and (c) as defined in claim 1, to obtain a compound of formula I



I

and the alkylation reaction by addition to I of a compound of formula J = R_1-L-Lg in which R_1 and L are as defined in any one of the preceding claims and Lg is a leaving group.

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, comprising the alkylation reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, by addition of a compound of formula J = R_1-L-Lg in which R_1 and L are as defined in any one of claims 1 to 8 and Lg is a leaving group, to obtain a compound of formula K



K

in which R_1, R_2, L and n are as defined in one of claims 1 to 8, and a reaction on a

compound K with a compound of formula Y being a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1.

15. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is an ethyl group, R_1 is a linear or branched (C_1-C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising a Michael addition reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, on a compound of formula M = CH_2=CH_2-CO_2Alkyl, to obtain a compound of formula N,



N

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, and Y is a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1,
and a reaction of alkyl on a compound of formula N with a compound of formula O = Z-Mg-X in which Z represents a linear or branched alkyl radical and X is a halogen atom.

16. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a linear or branched (C_1-C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising an addition reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a compound of formula P = X-CH_2-CO_2Alkyl with X being a halogen atom, to obtain a compound of formula Q



Q

in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0,

and an alkylation reaction on a compound of formula Q with a compound of formula O = Z-Mg-X in which Z represents a linear or branched alkyl radical and X is a halogen atom.

17. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a group -$NR_6R_{6'}$ with R_6 et $R_{6'}$ being either different and representing an alkyl group and an alkoxy group, or R_6 and $R_{6'}$ together forming a monocyclic or bicyclic heterocycloalkyl, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising a hydrolysis reaction of a compound of formula Q



Q

in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and

R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, to obtain a compound of formula S



S

in which Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0,

and a coupling reaction between a compound of formula S and a compound of formula $HNR_6R_{6'}$ with R_6 and $R_{6'}$ being either different and representing an alkyl group and an alkoxy group, or R_6 and $R_{6'}$ together forming a monocyclic or bicyclic heterocycloalkyl.

18. Compounds of formulae I, N, Q and S:



I

,



N

,



Q

and



S

in which n, R_2 and Y are as defined in claim 1.

19. A medicament, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or an addition salt of this compound with a pharmaceutically acceptable acid or base.

20. The compound as claimed in any one of claims 1 to 12, as a medicament.

21. A pharmaceutical composition, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

22. The use of a compound as claimed in any one of claims 1 to 12, for the preparation of a medicament for treating parasite-induced malaria.

23. The compound as claimed in any one of claims 1 to 12, for its use in the treatment of malaria induced by all species of *Plasmodium*, such as *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and *P. knowlesi*, by all species of *Trypanosoma* and by all species of *Leishmania*, in the treatment of sleeping sickness, the treatment of Chagas disease, the various forms of leishmaniasis and the treatment of other parasitic infections, such as schistosomiasis (bilharzia), toxoplasmosis and coccidiosis.

CLAIMS

1. A compound corresponding to formula (I):



(I)

in which:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a) (b) (c)

- L represents a linker $–CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or a (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group and a hydroxyl group;
- R_1 represents:
  - a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group and a trifluoromethyl group,
  - a (C_3-C_6)cycloalkyl group, optionally substituted with a hydroxyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-NH_2$ group, a urea group of formula $–NH-CO-NH-(C_1-C_4)$alkyl, a morpholine group, a group of formula $-SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,

- a hydroxyl group or a (C_1-C_5)alkoxy group,
- a group -COR_3, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group -$CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a group -$NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

- R_2 represents a hydrogen atom when n represents 1 and a methyl group when

n represents 0;

- R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

2. The compound of formula (I) as claimed in claim 1, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a) (b) (c)

- L represents a linker –CH_2-CO- such that the carbonyl function is attached to the substituent R_1, or a (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group and a hydroxyl group;
- R_1 represents:
  - a linear or branched (C_1-C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
  - a (C_3-C_6)cycloalkyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an -NH_2 group, a urea group of formula –NH-CO-NH-(C_1-C_4)alkyl, a morpholine group, a group of formula -SO_2-(C_1-C_5)alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a hydroxyl group or a (C_1-C_5)alkoxy group,
    - a group -COR_3, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
    - a group -$CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
    - a group -$NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
    - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,

- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

3. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

➢ Y represents a bridged morpholine (a)



(a)

in the form of the base or of an addition salt with an acid or with a base.

4. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine (a)



(a)

- L represents a linker $–CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group;
- R_1 represents:
  - a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group, a trifluoromethyl group and a (C_3-C_6)cycloalkyl group,
  - a (C_3-C_6)cycloalkyl group, optionally substituted with a hydroxyl group,
  - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-NH_2$ group, a urea group of formula -NH-CO-NH-(C_1-C_4)alkyl, a morpholinyl group, a group of formula $–SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a hydroxyl group or a (C_1-C_5)alkoxy,
    - a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
    - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
    - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and

an -NH_2 group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,
  - a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

5. The compound of formula (I) as claimed in any one of claims 1 to 4, characterized in that:

➢ n represents 0 or 1;

➢ Y represents a bridged morpholine (a)



(a)

➢ L represents a linker $–CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3)alkyl group;

➢ R_1 represents:

- a linear, branched, cyclic or partially cyclic (C_1-C_5)alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- a (C_3-C_6)cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-NH_2$ group, a urea group of formula -NH-CO-NH-(C_1-C_4)alkyl, a morpholinyl group, a group of formula $–SO_2-(C_1-C_5)$alkyl, a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a hydroxyl group or a (C_1-C_5)alkoxy,
  - a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
  - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
  - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an $-NH_2$ group,
- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a (C_1-C_3)alkyl group optionally substituted with one or more halogen atoms,
  - a (C_1-C_5)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents

chosen from a halogen atom, a (C_1-C_3)alkyl group, a hydroxyl group and an -NH_2 group,

- a group –$NR_5R_{5'}$ in which R_5 and $R_{5'}$, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO_2-(C_1-C_3)alkyl group, a (C_3-C_5)cycloalkyl group and a linear or branched (C_1-C_3)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,

- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
- a group –$NR_6R_{6'}$ in which R_6 and $R_{6'}$, which are different, represent a (C_1-C_5)alkyl group and a (C_1-C_5)alkoxy group,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

6. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

➢ n represents 0 or 1;

➢ Y represents a bridged morpholine chosen from (b) and (c)



(b) (c)

➢ L represents a linker –CH_2-CO- such that the carbonyl function is attached to the substituent R_1, or (C_1-C_2)alkyl, said alkyl being optionally substituted with a hydroxyl group;

➢ R_1 represents:

- a linear or branched (C_1-C_5)alkyl group, optionally substituted with an aryl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group and a (C_1-C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
    - a group -$CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
    - a group -$NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heteroaryl group comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more (C_1-C_3)alkyl groups, optionally substituted with one or more halogen atoms,

➢ R_2 represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➢ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

7. The compound as claimed in any one of claims 1 to 6, characterized in that the linker L represents –CH_2-CO, in the form of the base or of an addition salt with an acid or with a base.

8. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 1, in the form of the base or of an addition salt with an acid or with a base.

9. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 0, in the form of the base or of an addition salt with an acid or with a base.

10. The compound as claimed in any one of claims 1 to 9, characterized in that R_1 represents a heteroaryl group, in the form of the base or of an addition salt with an acid or with a base.

11. The compound as claimed in any one of claims 1 to 9, characterized in that R_1 represents a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO_2-(C_1-C_4)alkyl group, in the form of the base or of an addition salt with an acid or with a base.

12. The compound as claimed in any one of the preceding claims 1 to 11, characterized in that it is chosen from:

1 (8S)-9-(2-Methyl-2-pyrid-4-ylpropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

2 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

3 (8S)-9-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

4 (8S)-9-[2-(6-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

5 (8S)-9-[2-(6-Methylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

6 (8S)-9-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

7 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

8 1-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(S)-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

9 2-(S)-Methyl-1-[2-(6-methylaminopyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

10 (8S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-

azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

11 (S)-1-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

12 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

13 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

14 (8S)-9-{2-[6-(2-Hydroxyethylamino)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

15 (8S)-9-[2-(5-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

16 2-Methyl-1-[2-(5-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

17 2-Methyl-1-[2-(6-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

18 2-Methyl-1-[2-(2-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

19 (8S)-9-[2-(2-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

20 (8S)-9-[2-(4-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-

4-one

21 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-oxo-2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

22 (8S)-9-[2-(6-Cyclopropylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

23 1-Ethyl-3-{4-[2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea

24 1-Ethyl-3-{4-[2-((S)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea

25 (8S)-9-[2-(4-Methylthiazol-5-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

26 2-Methyl-1-[2-(4-methylthiazol-5-yl)ethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

27 (8S)-9-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

28 1-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

29 (8S)-9-(3,3-Dimethyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

30 1-(3,3-Dimethyl-2-oxobutyl)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

31 (8S)-9-[2-(6-Amino-5-methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

32 1-[2-(4-Aminophenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

33 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(6-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

34 (8S)-9-(2-{6-[(2-Hydroxyethyl)methylamino]pyrid-3-yl}-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

35 (8S)-9-[2-(6-Ethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

36 (8S)-9-[2-(6-Amino-4,5-dimethylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

37 (S)-9-[2-(4-Difluoromethoxyphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

38 (8S)-9-[2-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

39 (8S)-9-[2-(4-Methyloxazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

40 (S)-9-[2-(3,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

41 (8S)-9-[2-(4-Morpholin-4-ylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

42 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile

43 (8S)-9-[2-(4-Methylthiazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

44 (8S)-9-[2-(5-Chloropyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

45 (8S)-9-[2-(6-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

46 (8S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

47 (8S)-9-(2-Benzo[1,2,3]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

48 (8S)-9-[2-(2,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

49 (8S)-9-(3-Ethyl-3-hydroxypentyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

50 (8S)-9-(3-Hydroxy-3-methylbutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

51 (8S)-9-(1-Methyl-1H-indazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

52 (8S)-9-[2-(2-Cyclopropylmethoxypyrimidin-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

53 (8S)-9-[2-(3,5-Dimethylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

54 (8S)-9-(2-Ethyl-2-hydroxybutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

55 3-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile

56 (8S)-9-(3-Methyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

57 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid ethyl ester

58 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid methyl ester

59 (8S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

60 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(2-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

61 (8S)-9-(2-Benzo[1,2,5]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

62 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

63 (8S)-9-{2-[6-(2-Fluoroethoxy)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

64 (8S)-9-{2-[3-Fluoro-4-(2-fluoroethoxy)phenyl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

65 (8S)-9-[2-(2-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

66 (8S)-9-[2-(3-Methyl-3H-imidazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

67 (8S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

68 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

69 (8S)-9-[2-(2-Methyl-2H-pyrazol-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

70 N,N-Dimethyl-2-(4-{2-[(S)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl]ethyl}phenoxy)acetamide

71 (8S)-9-[(S)-2-(4-Fluoro-2-methoxyphenyl)-2-hydroxyethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

72 (2S)-1-[2-(4-Hydroxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

73 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

74 (2S)-1-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

75 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

76 (S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

77 (S)-2-Methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(3-phenylpropyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

78 (S)-1-{2-[4-(3-Dimethylaminopropoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

79 (2S)-1-((S)-2-Hydroxy-2-phenylethyl)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

80 (8S)-9-((S)-2-Hydroxy-2-phenylethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

81 (8S)-9-[2-(4-Methoxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

82 (8S)-9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxyethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

83 (8S)-9-[2-(4-Hydroxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

84 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(3-phenylpropyl)-8-trifluoromethylmethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

85 (8S)-2-(3-Oxa-8-azabicyclo[3.2.1]oct-8-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

86 (8S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

87 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

88 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

89 (S)-9-[2-(1-Acetylpiperid-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

90 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]piperidine-1-carbaldehyde

91 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carboxylic acid ethyl ester

92 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

93 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(tetrahydropyran-4-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

94 (8S)-9-(1-Acetylpiperid-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

95 4-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carbaldehyde

96 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(3,3,3-trifluoro-2-hydroxy-2-trifluoromethylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

97 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(4,4,4-trifluoro-3-hydroxy-3-trifluoromethylbutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

98 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

99 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

100 (8S)-9-[2-(1-Hydroxycyclopentyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

101 (8S)-9-(1-Hydroxycyclopentylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

102 (8S)-9-(3,3-Dicyclopropyl-3-hydroxypropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

103 (8S)-9-(2,2-Dicyclopropyl-2-hydroxyethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

104 (8S)-9-(1-Hydroxycyclopropylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

105 (8S)-9-[2-(1-Hydroxycyclopropyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

106 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-quinolin-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

107 (8S)-9-[2-(3-Methylisothiazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

108 (8S)-9-[2-(4-Methanesulfonylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

109 (8S)-9-Isoquinolin-5-ylmethyl-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

110 (8S)-9-(2-Morpholin-4-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-

yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

111 (8S)-9-{2-[4-(2-Morpholin-4-ylethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

112 N-Methoxy-N-methyl-2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetamide

113 (8S)-9-(2-Imidazo[1,2-a]pyrid-6-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

114 (8S)-9-[2-(6-Difluoromethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

115 (S)-9-{2-[4-(2-Morpholin-4-yl-2-oxoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

116 (8S)-9-(1-Methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

117 (8S)-9-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

118 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carbaldehyde

119 (8S)-9-[2-(1-Acetylpiperid-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

in the form of the base or of an addition salt with an acid or with a base.

13. A process for preparing a compound of formula (I) as claimed in any one of claims

1 to 12, comprising the reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a bridged morpholine Y, chosen from (a), (b) and (c) as defined in claim 1, to obtain a compound of formula I



I

and the alkylation reaction by addition to I of a compound of formula J = R_1-L-Lg in which R_1 and L are as defined in any one of the preceding claims and Lg is a leaving group.

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, comprising the alkylation reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, by addition of a compound of formula J = R_1-L-Lg in which R_1 and L are as defined in any one of claims 1 to 8 and Lg is a leaving group, to obtain a compound of formula K



K

in which R_1, R_2, L and n are as defined in one of claims 1 to 8, and a reaction on a

compound K with a compound of formula Y being a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1.

15. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is an ethyl group, R_1 is a linear or branched (C_1-C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising a Michael addition reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, on a compound of formula M = CH_2=CH_2-CO_2Alkyl, to obtain a compound of formula N,



N

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, and Y is a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1,

and a reaction of alkyl on a compound of formula N with a compound of formula O = Z-Mg-X in which Z represents a linear or branched alkyl radical and X is a halogen atom.

16. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a linear or branched (C_1-C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising an addition reaction of a compound of formula E



E

in which n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a compound of formula P = X-CH_2-CO_2Alkyl with X being a halogen atom, to obtain a compound of formula Q



Q

in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0,

and an alkylation reaction on a compound of formula Q with a compound of formula O = Z-Mg-X in which Z represents a linear or branched alkyl radical and X is a halogen atom.

17. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a group -$NR_6R_{6'}$ with R_6 and $R_{6'}$ being either different and representing an alkyl group and an alkoxy group, or R_6 and $R_{6'}$ together forming a monocyclic or bicyclic heterocycloalkyl, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when n = 1 and a methyl group when n = 0, comprising a hydrolysis reaction of a compound of formula Q



Q

in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and

R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0, to obtain a compound of formula S



S

in which Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0 and R_2 represents a hydrogen atom when n = 1 or a methyl group when n = 0,

and a coupling reaction between a compound of formula S and a compound of formula $HNR_6R_{6'}$ with R_6 and $R_{6'}$ being either different and representing an alkyl group and an alkoxy group, or R_6 and $R_{6'}$ together forming a monocyclic or bicyclic heterocycloalkyl.

18. Compounds of formulae I, N, Q and S:



I

,



N

,



Q

and



S

in which n, R_2 and Y are as defined in claim 1.

19. A medicament, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or an addition salt of this compound with a pharmaceutically acceptable acid or base.

20. The compound as claimed in any one of claims 1 to 12, as a medicament.

21. A pharmaceutical composition, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

22. The use of a compound as claimed in any one of claims 1 to 12, for the preparation of a medicament for treating parasite-induced malaria.

23. The compound as claimed in any one of claims 1 to 12, for use in the treatment of malaria induced by all species of *Plasmodium*, such as *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and *P. knowlesi*, by all species of *Trypanosoma* and by all species of *Leishmania*, in the treatment of sleeping sickness, the treatment of Chagas disease, the various forms of leishmaniasis and the treatment of other parasitic infections, such as schistosomiasis (bilharzia), toxoplasmosis and coccidiosis.